These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2526150)

  • 21. Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
    Ulbricht A; Färber I; Wutzler P
    Acta Virol; 1985 Dec; 29(6):493-8. PubMed ID: 2869661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon.
    Hartshorn KL; Sandstrom EG; Neumeyer D; Paradis TJ; Chou TC; Schooley RT; Hirsch MS
    Antimicrob Agents Chemother; 1986 Jul; 30(1):189-91. PubMed ID: 3019235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical toxicological study of phosphonoacetic acid: determination in blood by selected ion monitoring.
    Roboz J; Suzuki R; Bekesi G; Hunt R
    Biomed Mass Spectrom; 1977 Oct; 4(5):291-6. PubMed ID: 410465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Foscarnet.
    Lancet; 1985 Sep; 2(8456):648-9. PubMed ID: 2863637
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
    Gaub J; Pedersen C; Poulsen AG; Mathiesen LR; Ulrich K; Lindhardt BO; Faber V; Gerstoft J; Hofmann B; Lernestedt JO
    AIDS; 1987 May; 1(1):27-33. PubMed ID: 2962590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Foscarnet for cytomegalovirus infections.
    Ringdén O; Wilczek H; Lönnqvist B; Gahrton G; Wahren B; Lernestedt JO
    Lancet; 1985 Jun; 1(8444):1503-4. PubMed ID: 2861426
    [No Abstract]   [Full Text] [Related]  

  • 27. Mode of action of phosphonoformate as an anti-herpes simplex virus agent.
    Cheng YC; Grill S; Derse D; Chen JY; Caradonna SJ; Connor K
    Biochim Biophys Acta; 1981 Jan; 652(1):90-8. PubMed ID: 6260189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Foscarnet for cytomegalovirus pneumonitis.
    Apperley JF; Marcus RE; Goldman JM; Wardle DG; Gravett PJ; Chanas A
    Lancet; 1985 May; 1(8438):1151. PubMed ID: 2860348
    [No Abstract]   [Full Text] [Related]  

  • 29. Foscarnet in fulminant hepatitis B.
    Price JS; France AJ; Moaven LD; Welsby PD
    Lancet; 1986 Nov; 2(8518):1273. PubMed ID: 2878146
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
    Weber JN; Thom S; Barrison I; Unwin R; Forster S; Jeffries DJ; Boylston A; Pinching AJ
    Gut; 1987 Apr; 28(4):482-7. PubMed ID: 3034745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir.
    Al-Samarai A; Kinghorn G; Potter C
    Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616
    [No Abstract]   [Full Text] [Related]  

  • 32. Foscarnet-induced acute renal failure and effectiveness of haemodialysis.
    Deray G; Cacoub P; Le Hoang P; Baumelou A; Soubrie C; Rousselie F; Morer I; Jacobs C
    Lancet; 1987 Jul; 2(8552):216. PubMed ID: 2885666
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
    Sjövall J; Karlsson A; Ogenstad S; Sandström E; Saarimäki M
    Clin Pharmacol Ther; 1988 Jul; 44(1):65-73. PubMed ID: 2968875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of topical foscarnet in a new model of herpes simplex skin infection.
    van Genderen J; Wolthuis OL; Ariens AT; Ericson AC; Datema R
    J Antimicrob Chemother; 1987 Oct; 20(4):547-56. PubMed ID: 2960644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Foscarnet for cytomegalovirus retinitis.
    Singer DR; Fallon TJ; Schulenburg WE; Williams G; Cohen J
    Ann Intern Med; 1985 Dec; 103(6 ( Pt 1)):962. PubMed ID: 2998255
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of HTLV-III/LAV replication by foscarnet.
    Sarin PS; Taguchi Y; Sun D; Thornton A; Gallo RC; Oberg B
    Biochem Pharmacol; 1985 Nov; 34(22):4075-9. PubMed ID: 2415134
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.
    Youle MS; Clarbour J; Gazzard B; Chanas A
    Lancet; 1988 Jun; 1(8600):1455-6. PubMed ID: 2898602
    [No Abstract]   [Full Text] [Related]  

  • 38. "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
    Hussain AS; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1989 Feb; 11(2):111-4. PubMed ID: 2523506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
    Erlich KS; Jacobson MA; Koehler JE; Follansbee SE; Drennan DP; Gooze L; Safrin S; Mills J
    Ann Intern Med; 1989 May; 110(9):710-3. PubMed ID: 2522751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
    Farthing CF; Dalgleish AG; Clark A; McClure M; Chanas A; Gazzard BG
    AIDS; 1987 May; 1(1):21-5. PubMed ID: 2962589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.